source
- FDA approves Isembyld, first therapy to target muscle loss in SMA patientsScholar Rock received FDA approval for Isembyld, the first drug designed to address muscle loss in spinal muscular atrophy (SMA). The approval covers adults and children aged two years and older w…
- Disc sets up polycythemia vera challenge but Silence maintains leadThe polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, who won the…